1. Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies. Issue 7 (14th February 2022) Authors: Meng, Amy; Anderson, Kacey; Nelson, Cara; Ni, Liyun; Chuang, Shu‐Min; Bellanti, Francesco; Chang, Peter; Comisar, Craig; Kearney, Brian P.; Bartok, Beatrix; Mathias, Anita Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 7(2022) Page Start: 3211 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IDDF2019-ABS-0135 Pharmacokinetics of once-daily sofosbuvir or ledipasvir/sofosbuvir in HCV-infected pediatrics aged 3 to. (June 2019) Authors: Begley, Rebecca; Meng, Amy; Massetto, Benedetta; Shao, Jiang; Sze Man Yip, Christina; Ling, John; Mathias, Anita Journal: Gut Issue: Volume 68(2019)Supplement 1 Page Start: A137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Issue 7 (19th March 2021) Authors: Traves, Paqui G; Murray, Bernard; Campigotto, Federico; Galien, René; Meng, Amy; Di Paolo, Julie A Journal: Annals of the rheumatic diseases Issue: Volume 80:Issue 7(2021) Page Start: 865 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Phase 1 First‐in‐Human, Single‐ and Multiple‐Ascending Dose, and Food Effect Studies to Assess the Safety, Tolerability, and Pharmacokinetics of Presatovir for the Treatment of Respiratory Syncytial Virus Infection. (17th April 2018) Authors: German, Polina; Xin, Yan; Chien, Jason W.; Weng, Winnie; Mackman, Richard; Lewis, Sandra A.; Meng, Amy; Ling, John; Mathias, Anita Journal: Journal of clinical pharmacology Issue: Volume 58:Number 8(2018) Page Start: 1025 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Semi‐Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA. Issue 2 (27th October 2021) Authors: Meng, Amy; Humeniuk, Rita; Jürgensmeier, Juliane M.; Hsueh, Chia‐Hsiang; Matzkies, Franziska; Grant, Ethan; Truong, Hoa; Billin, Andrew N.; Yu, Helen; Feng, Joy; Kwan, Ellen; Tarnowski, Thomas; Nelson, Cara H. Journal: Clinical pharmacology & therapeutics Issue: Volume 111:Issue 2(2022) Page Start: 416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THU0017 IN VITRO MECHANISTIC STUDIES DEMONSTRATE FILGOTINIB ACTIVITY THAT HAS POTENTIAL IMPLICATIONS FOR DIFFERENTIATION AMONG JAK INHIBITORS. (June 2019) Authors: Han, Pei; Meng, Amy; Mollova, Nevena; Yu, Yuanjiang; DI Paolo, Julie A. Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 276 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗